|
Company Name: Navigantbiotech
Company Type: Discovering and Developing Natural Innovations for Blood Safety
Company Profile
Founded in 2002, Navigant Biotechnologies is a wholly owned subsidiary of
Gambro, Inc., global leader in renal care, healthcare services, and
blood-component technologies. In 1998, Gambro subsidiary, Gambro BCT, started a
research program applying riboflavin to collected blood cells to inactivate
pathogens, with the ultimate goal being an increased level of blood safety.
Since that time, rigorous research and development have been pursued to
demonstrate the effectiveness and safety of the compound. Most recently, Gambro
established Navigant Biotechnologies as a separate company to better capture the
full potential of its innovative pathogen reduction technology.
Gambro, Inc.
Gambro BCT
General Information
Currently 38 full time staff-members and contractors are employed by Navigant
Biotechnologies. Located in Lakewood, Colorado, Navigant Biotechnologies also
has an office in Brussels, Belgium.
Financial Information
Navigant Biotechnologies is a wholly owned subsidiary of Gambro, Inc. Parent
company Gambro AB is publicly traded on the Stockholm Stock Exchange.
Gambro AB
Investor Information
About Company
Navigant Biotechnologies is focused on discovering and developing natural innovations for blood safety. At the core of Navigant's unique technology are riboflavin and light, a completely safe and effective solution to pathogen reduction. The philosophy that drives the research and development at Navigant Biotechnologies is the search for natural solutions that are simple to integrate, safe for healthcare workers and patients, and most important, effective in reducing pathogens.
Navigant Biotechnologies' mission is "To improve the safety and trust in the world's blood supply."
Navigant Biotechnologies is focused on developing and delivering a riboflavin-based technology to reduce disease-causing viruses, bacteria, and parasites and neutralize white blood cells within blood components.
|
